In a novel approach, CoFe₂O₄/mSiO₂-NH₂/Poly(MAA-co-IA)/MF₃ as a core/double shells (CDS) magnetic-luminescent nanomaterial is reported and it was characterized by XRD, SEM, EDS, VSM, BET, TEM and FT-IR techniques. Analyses exhibited that the diameter of core/double shells was about 35 nm with surface area and pore diameter of 220 m².g⁻¹ & 2.44 nm, respectively. The nanocomposite was used as a nanocarrier for methotrexate (MTX) and doxorubicin (DOX), simultaneously, as anti-cancer drugs, against MCF-7 human breast cancer cells. Two drugs were successfully loaded 51 (MTX) and 75 % (DOX) within the nanocomposite. The nanocarrier was designed to be sensitive to pH and it demonstrated a controlled drug release that can be able to distinguish between normal and cancer tissues. The biocompatibility studies of the nanocarrier showed very low cytotoxicity against Primary Human Umbilical Vein Endothelial Cells (HUVEC). Also, the in vitro cytotoxic studies against MCF-7 cells of the MTX@DOX-NPs demonstrated a noticeable tumor inhibition compared with the free forms of drugs. Based on the results, the magnetic-luminescent nanocomposites have an excellent potential for simultaneous delivery of two drugs and can provide promising prospects in cancer therapy.

报道了一种新方法，CoFe ₂ O ₄ /mSiO ₂ -NH ₂ /Poly(MAA-co-IA)/MF ₃作为核/双壳(CDS)磁致发光纳米材料，并通过XRD、SEM对其进行了表征、EDS、VSM、BET、TEM 和 FT-IR 技术。分析表明，核/双壳的直径约为 35 nm，表面积和孔径为 220 m ² .g ^-1& 2.44 纳米，分别。该纳米复合材料被用作甲氨蝶呤 (MTX) 和多柔比星 (DOX) 的纳米载体，同时作为抗癌药物，对抗 MCF-7 人乳腺癌细胞。两种药物在纳米复合材料中成功加载了 51% (MTX) 和 75% (DOX)。纳米载体被设计成对 pH 值敏感，它显示出可控的药物释放，能够区分正常组织和癌组织。纳米载体的生物相容性研究表明对原代人脐静脉内皮细胞 (HUVEC) 的细胞毒性非常低。此外，针对 MTX@DOX-NPs 的 MCF-7 细胞的体外细胞毒性研究表明，与游离形式的药物相比，它具有明显的肿瘤抑制作用。根据结果​​，